Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 51 Published: July 29, 2022 Report Code: GDGMDHC22144TDB

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor – Drugs In Development, 2022, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 9 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neuropathic Pain (Neuralgia), Epilepsy, Glaucoma, Ischemic Stroke, Keratitis, Keratoconjunctivitis Sicca (Dry Eye), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Peripheral Nerve Injury, Radiculopathy, Retinitis Pigmentosa (Retinitis) and Unspecified Ophthalmological Disorders.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

– The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

Asklepios BioPharmaceutical Inc

Biogen Inc

Copernicus Therapeutics Inc

Eli Lilly and Co

Kai Nuo Bio Sci Co Ltd

Kolon Life Science Inc

Lauren Sciences LLC

Neuroptika Inc

Sinfonia Biotherapeutics Inc

Stem Cell Medicine Ltd

Treeway BV

UniQure NV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Overview

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Companies Involved in Therapeutics Development

Asklepios BioPharmaceutical Inc

Biogen Inc

Copernicus Therapeutics Inc

Eli Lilly and Co

Kai Nuo Bio Sci Co Ltd

Kolon Life Science Inc

Lauren Sciences LLC

Neuroptika Inc

Sinfonia Biotherapeutics Inc

Stem Cell Medicine Ltd

Treeway BV

UniQure NV

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Drug Profiles

AMT-090 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs for Neurodegenerative Diseases – Drug Profile

Product Description

Mechanism Of Action

EpiRepair – Drug Profile

Product Description

Mechanism Of Action

Fusion Protein to Activate GDNF for Brain Ischemia – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis Pigmentosa – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate GDNF for Multiple System Atrophy and Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate GDNF for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

KLS-2031 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LAUR-101 – Drug Profile

Product Description

Mechanism Of Action

LAUR-301 – Drug Profile

Product Description

Mechanism Of Action

NRO-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Protein to Activate GDNF for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

ST-502 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain – Drug Profile

Product Description

Mechanism Of Action

History of Events

TW-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Dormant Products

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Product Development Milestones

Featured News & Press Releases

Jun 18, 2021: CIRM Board approves new clinical trial for ALS

Aug 17, 2020: Neuroptika completes enrollment in phase 2 clinical trial for Dry Eye Disease

Apr 27, 2020: Kolon Life Sciences launches follow-up pipeline to administer the first patient in the US

Jan 17, 2020: Neuroptika enrols first patient for dry eye disease trial

Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial

Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain

Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment

Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment

Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients

Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association

Dec 13, 2010: Sangamo Announces Publication Of Data From Program To Develop ZFP Therapeutic For Parkinson's Disease In Journal Of Neuroscience.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Asklepios BioPharmaceutical Inc, 2022

Pipeline by Biogen Inc, 2022

Pipeline by Copernicus Therapeutics Inc, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Kai Nuo Bio Sci Co Ltd, 2022

Pipeline by Kolon Life Science Inc, 2022

Pipeline by Lauren Sciences LLC, 2022

Pipeline by Neuroptika Inc, 2022

Pipeline by Sinfonia Biotherapeutics Inc, 2022

Pipeline by Stem Cell Medicine Ltd, 2022

Pipeline by Treeway BV, 2022

Pipeline by UniQure NV, 2022

Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.